CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD.

Chunghwa Chemical Synthesis & Biotech Co., Ltd.

1762

TW0001762003

Pharmaceuticals

End-of-day quote Taiwan S.E. Other stock markets 18:00:00 2024-06-13 EDT			5-day change	1st Jan Change
48.8 ^TWD	+0.83%		+1.04%	-14.98%

05-30	Chunghwa Chemical Synthesis & Biotech Co., Ltd. Elects Hou-Kai as Vice Chairman	CI
05-30	Chunghwa Chemical Synthesis & Biotech Co., Ltd. Approves Cash Dividend for the Year 2023	CI

Chunghwa Chemical Synthesis & Biotech Co., Ltd.(TSEC:1762) added to S&P Global BMI Index

September 21, 2020 at 12:00 am

Latest news about Chunghwa Chemical Synthesis & Biotech Co., Ltd.

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Elects Hou-Kai as Vice Chairman	05-30	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Approves Cash Dividend for the Year 2023	05-30	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. cancelled the transaction announced on March 11, 2024	03-10	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend for the Year 2022, Payable on August 18, 2023	23-06-27	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend for the Year 2022	23-05-30	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. announced a financing transaction	23-03-06	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Dividend, Payable on August 18, 2022	22-06-28	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Appointment of Kuan Arthur¡G as Independent Director	22-05-25	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Approves Cash Dividend for 2021	22-05-25	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-11	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-13	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend, Payable on August 18, 2021	21-07-01	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-14	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-30	CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-12	CI

Chart Chunghwa Chemical Synthesis & Biotech Co., Ltd.

Duration

Period

Chart Chunghwa Chemical Synthesis & Biotech Co., Ltd.

More charts

CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

48.8 TWD

Average target price

48 TWD

Spread / Average Target

-1.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD.	-14.98%	116M
CSL LIMITED	+0.85%	92.4B
SAMSUNG BIOLOGICS CO.,LTD.	-3.03%	38.08B
BIOGEN INC.	-10.46%	34.05B
UCB	+74.71%	27.77B
BIOMARIN PHARMACEUTICAL INC.	-13.39%	16B
INCYTE CORPORATION	-1.08%	14.1B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.15%	11.91B
ALTEOGEN INC.	+169.04%	10.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-50.19%	10.2B

Biopharmaceuticals